Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator
- PMID: 23072904
- DOI: 10.1161/CIRCULATIONAHA.111.069245
Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator
Erratum in
- Circulation. 2013 Apr 9;127(14):E541
Abstract
Background: Whether sex differences in implantable cardioverter-defibrillator (ICD) benefit exist remains unanswered. We evaluated sex differences in mode of death among a large cohort of ambulatory heart failure patients who meet criteria for a primary prevention ICD.
Methods and results: Patients from 5 trials or registries were included if they met American College of Cardiology/American Heart Association/Heart Rhythm Society guideline criteria for implantation of a primary prevention ICD. We investigated the potential sex differences in total deaths and total deaths by mode of death. The relationship between the estimated total mortality and mode of death by percentage of total mortality was also analyzed by sex. The Seattle Heart Failure Model was used to estimate total mortality in this analysis. A total of 8337 patients (1685 [20%] women) met inclusion criteria. One-year mortality was 10.8±0.3%. In women, the age-adjusted all-cause mortality was 24% lower (hazard ratio [HR], 0.76; confidence interval [CI], 0.68-0.85; P<0.0001), the risk of sudden death was 31% lower (HR, 0.69; CI, 0.58-0.83; P<0.0001), but no significant difference in pump failure death was observed. Throughout a range of total mortality risk, women had a 20% lower all-cause mortality (HR, 0.80; CI, 0.71-0.89; P<0.001) and 29% fewer deaths that were sudden (HR, 0.71; CI, 0.59-0.86;P<0.001) compared with men.
Conclusions: Women with heart failure have a lower mortality than men, and fewer of those deaths are sudden throughout a spectrum of all-cause mortality risk. These data provide a plausible reason for and thus support the possibility that sex differences in ICD benefit may exist.
Similar articles
-
Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.Arch Intern Med. 2009 Sep 14;169(16):1500-6. doi: 10.1001/archinternmed.2009.255. Arch Intern Med. 2009. PMID: 19752408
-
Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.Heart. 2013 Aug;99(16):1158-65. doi: 10.1136/heartjnl-2013-304185. Epub 2013 Jun 27. Heart. 2013. PMID: 23813845
-
Clinical effectiveness of cardiac resynchronization and implantable cardioverter-defibrillator therapy in men and women with heart failure: findings from IMPROVE HF.Circ Heart Fail. 2014 Jan;7(1):146-53. doi: 10.1161/CIRCHEARTFAILURE.113.000789. Epub 2013 Oct 31. Circ Heart Fail. 2014. PMID: 24178311
-
New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.Am Heart J. 2017 Sep;191:21-29. doi: 10.1016/j.ahj.2017.06.002. Epub 2017 Jun 9. Am Heart J. 2017. PMID: 28888266 Free PMC article. Review.
-
[In patients with heart failure, do implantable cardioverter-defibrillators delay death or save lives?].Ital Heart J Suppl. 2002 Jan;3(1):36-44. Ital Heart J Suppl. 2002. PMID: 11899573 Review. Italian.
Cited by
-
Age and sex differences in long-term outcomes following implantable cardioverter-defibrillator placement in contemporary clinical practice: findings from the Cardiovascular Research Network.J Am Heart Assoc. 2015 Jun 2;4(6):e002005. doi: 10.1161/JAHA.115.002005. J Am Heart Assoc. 2015. PMID: 26037083 Free PMC article.
-
Sex Differences in Advanced Heart Failure Therapies.Circulation. 2019 Feb 19;139(8):1080-1093. doi: 10.1161/CIRCULATIONAHA.118.037369. Circulation. 2019. PMID: 30779645 Free PMC article. Review.
-
Survival Probability and Survival Benefit Associated With Primary Prevention Implantable Cardioverter-Defibrillator Generator Changes.J Am Heart Assoc. 2022 Jul 5;11(13):e023743. doi: 10.1161/JAHA.121.023743. Epub 2022 Jun 29. J Am Heart Assoc. 2022. PMID: 35766293 Free PMC article.
-
Sex Differences in Utilisation and Response to Implantable Device Therapy.Arrhythm Electrophysiol Rev. 2015 Aug;4(2):129-35. doi: 10.15420/aer.2015.04.02.129. Arrhythm Electrophysiol Rev. 2015. PMID: 26835114 Free PMC article.
-
Predicting long-term survival after de novo cardioverter-defibrillator implantation for primary prevention: A population based study.Heliyon. 2023 Dec 6;10(1):e23355. doi: 10.1016/j.heliyon.2023.e23355. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38223713 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous